Local and Systemic Safety and Tolerability of Ascending Doses of TOP-N53, a Nitric Oxide (NO)-Releasing Phosphodiesterase-5 (PDE5) Inhibitor, Administered Topically, on Wounds in Patients With Digital Ulcers (DU) in Systemic Sclerosis (SSc) in an Open-label, Vehicle-controlled, Phase 2a, Multi-center Clinical Trial
Latest Information Update: 10 May 2025
At a glance
- Drugs TOP N53 (Primary) ; Sildenafil
- Indications Skin ulcer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Topadur Pharma
Most Recent Events
- 01 May 2025 Status changed from planning to recruiting.
- 28 Mar 2022 New trial record